The first ever drug specifically designed to prevent a migraine has been given the green light by European health officials.
Erenumab is now expected to be considered by English and Scottish health agencies to assess whether it is appropriate for NHS use.
But manufacturer Novartis said that patients will be able to get the drug privately in September after the European Medicines Agency approved a licence for the drug for patients who have at least four migraines a month.
The drug, also known as aimovig, was designed to block the calcitonin gene-related peptide receptor, thought to be involved in migraine activation.
